shutterstock_1854498166_viacheslav_lopatin
Viacheslav Lopatin / Shutterstock.com
5 September 2023BiotechnologyMarisa Woutersen

UN race committee says global north’s COVID-19 IP position violates human rights

UN Committee on Racial Discrimination calls for equitable access to vaccines, treatments, and health tech | Switzerland, Germany, UK, and US refusal to waive IP rights for COVID-19 vaccines 'aids discrimination against vulnerable communities'.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
29 August 2023   Inter partes review challenges broad claims and monopolisation over mRNA tech amidst existing legal dispute | Alnylam set to appeal separate court ruling against Moderna.
Big Pharma
30 May 2023   A US biotech is accusing the pair of infringing several of its “foundational” lipid particle patents | Pfizer and BioNTech accused plaintiff in earlier suit of antitrust in a dispute over one of the patents at issue.

More on this story

Big Pharma
30 May 2023   A US biotech is accusing the pair of infringing several of its “foundational” lipid particle patents | Pfizer and BioNTech accused plaintiff in earlier suit of antitrust in a dispute over one of the patents at issue.
Big Pharma
29 August 2023   Inter partes review challenges broad claims and monopolisation over mRNA tech amidst existing legal dispute | Alnylam set to appeal separate court ruling against Moderna.

More on this story

Big Pharma
30 May 2023   A US biotech is accusing the pair of infringing several of its “foundational” lipid particle patents | Pfizer and BioNTech accused plaintiff in earlier suit of antitrust in a dispute over one of the patents at issue.
Big Pharma
29 August 2023   Inter partes review challenges broad claims and monopolisation over mRNA tech amidst existing legal dispute | Alnylam set to appeal separate court ruling against Moderna.